Stock Market Today: Stocks Dip as Israel’s Iran Attack Drives Oil Prices Higher
U.S. Consumer Confidence Shows First Positive Shift in 2025 as Economic Concerns Ease
U.S. consumer confidence showed its first signs of improvement so far in 2025, signaling that Americans have begun to feel more positive surrounding the country’s economic trajectory.
Viking Holdings Could Be the Next Top Performing Cruise Stock — Is It A Buying Opportunity?
Circle’s IPO Triggers ETF Surge as Crypto Enters Mainstream Investment Landscape
Stock Market Today: Stocks Hold Steady as Investors Wait on US-China Trade Talks
Business & Market Movers

Arista Networks’ Stunning Reversal: From Avoided To Adored — Why Wall Street Sees Strong Upside Ahead!
·Jun 13, 2025
Viking Holdings Could Be the Next Top Performing Cruise Stock — Is It A Buying Opportunity?
·Jun 11, 2025Breaking News
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”
Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled “Low Glycemic Sugar Composition” developed within this platform.

Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger
scdadmin·Dec 15, 2023Deep Dive & Research
Healthcare & Biotech
Bristol Myers’ $11.1 Billion Bet on BioNTech: Is Oncology The New Growth Engine?
Bristol Myers has inked a transformative partnership for BNT327, a bispecific PD-L1/VEGF-A antibody developed by BioNTech, with a $1.5 billion upfront payment and additional milestone-based payouts stretching through 2028.
Eli Lilly’s $1 Billion Bet On SiteOne: Can Non-Opioid Pain Drugs Reshape The Pharma Giant’s Future?





Arcutis Biotherapeutics Surges Amid Takeover Speculation: Why Large Pharma Should Pay Attention!


The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics

Join our newsletter
Read and share new perspectives on just about any topic. Everyone’s welcome.- 01Create a free account
- 02Write your story

Tech & Energy
Arista Networks’ Stunning Reversal: From Avoided To Adored — Why Wall Street Sees Strong Upside Ahead!
Over the past year, Arista Networks has staged one of the most impressive comebacks on Wall Street, transforming from a stock marred by tariff fears and competitive pressures into a top AI infrastructure play.

How AMD’s Enosemi Acquisition Pushes It Deeper Into The Co-Packaged Optics & AI Arms Race!


Motorola’s $4.4B Bet on Battlefield Networking: What the Silvus Acquisition Could Mean For Investors!


AT&T’s $5.75 Billion Fiber Power Play: What The Lumen Technologies Deal Means for Investors!

